| Literature DB >> 31264794 |
Rayane Ghoteimi1, Van Tai Nguyen1, Rahila Rahimova2, Felix Grosjean1, Emeline Cros-Perrial3, Jean-Pierre Uttaro1, Christophe Mathé1, Laurent Chaloin2, Lars Petter Jordheim3, Suzanne Peyrottes1.
Abstract
Derivatives of 5'-aminoadenosine containing methyl carboxylate, methyl phosphonate, gem-bisphosphonate, bis(methylphosphonate), and α-carboxylmethylphosphonate or phosphonoacetate moieties were synthesized from key intermediate 5'-aminonucleoside. These nucleotide analogues were envisaged as 5'-mono- or diphosphate nucleoside mimics. All compounds were evaluated for CD73 inhibition in a cell-based assay (MDA-MB-231) and toward the purified recombinant protein. Most of them failed to reach significant inhibition of AMP hydrolysis by CD73 at 100 μm. Among the new compounds, the most interesting candidates, 5 (5'-deoxy-5'-N-phosphonomethyladenosine) and 7 (5'-deoxy-5'-N-(ethoxyphosphorylacetate)adenosine), inhibited recombinant CD73 by 36 and 46 % and cellular CD73 by 61 and 45 % at 100 μm, respectively. Molecular modeling partially explains this lack of activity, as the initially predicted docking scores had been encouraging, especially for compound 9.Entities:
Keywords: 5′-ectonucleotidase; cancer; enzyme inhibitors; immunotherapy; nucleotide analogues
Year: 2019 PMID: 31264794 DOI: 10.1002/cmdc.201900348
Source DB: PubMed Journal: ChemMedChem ISSN: 1860-7179 Impact factor: 3.466